Treatment of systemic scleroderma and generalized morphoea with coagulation factor XIII

A. V. Marzano, G. Gasparini, C. Colonna, E. Berti, R. Caputo

Research output: Contribution to journalArticle

Abstract

In the blood coagulation process, factor XIII is responsible for the stabilization of the fibrin clot. Thivolet et a. [10] have used this factor in the treatment of scleroderma, hypothesizing as to its ability to favour the degradation of the collagen that accumulates in the skin and in other affected organs. Based on these findings and on the in vitro studies of Paye et al. [24], we administered factor XIII to twelve patients, eight of whom were suffering from sys temic scleroderma, three from generalized morphoea and one from localized morphoea. All had severe, widespread skin sclerosis. The mean duration of treatment was 35.5 months. Both short- and long-term drug safety was excellent. After approximately ten months of treatment, skin sclerosis, as evaluated by a semiquantitative method, was markedly improved in 75% of the cases. Stabilization of the clinical signs and symptoms was also observed and in two cases of generalized morphoea continued administration was regarded as unnecessary. On the other hand, the efficacy of factor XIII on organ involvement proved unclear even though its administration in combination with traditional drugs, such as low-dose corticosteroids or D-penicillamine, seemed to improve respiratory function in several cases As a consequence, factor XIII can be propsed both as the choice treatment in generalized morphea accompanied by ingravescent skin sclerosis, and as a drug to be combined with traditional treatments in systemic scleroderma.

Original languageEnglish
Pages (from-to)459-466
Number of pages8
JournalEuropean Journal of Dermatology
Volume5
Issue number6
Publication statusPublished - 1995

Fingerprint

Localized Scleroderma
Factor XIII
Systemic Scleroderma
Sclerosis
Skin
Pharmaceutical Preparations
Therapeutics
Penicillamine
Blood Coagulation
Fibrin
Signs and Symptoms
Adrenal Cortex Hormones
Collagen
Safety

Keywords

  • Factor XIII
  • Generalized morphoea
  • Localized morphoea-systemic scleroderma

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of systemic scleroderma and generalized morphoea with coagulation factor XIII. / Marzano, A. V.; Gasparini, G.; Colonna, C.; Berti, E.; Caputo, R.

In: European Journal of Dermatology, Vol. 5, No. 6, 1995, p. 459-466.

Research output: Contribution to journalArticle

@article{3b814f8e04dc46c9ae009dcc56a5b073,
title = "Treatment of systemic scleroderma and generalized morphoea with coagulation factor XIII",
abstract = "In the blood coagulation process, factor XIII is responsible for the stabilization of the fibrin clot. Thivolet et a. [10] have used this factor in the treatment of scleroderma, hypothesizing as to its ability to favour the degradation of the collagen that accumulates in the skin and in other affected organs. Based on these findings and on the in vitro studies of Paye et al. [24], we administered factor XIII to twelve patients, eight of whom were suffering from sys temic scleroderma, three from generalized morphoea and one from localized morphoea. All had severe, widespread skin sclerosis. The mean duration of treatment was 35.5 months. Both short- and long-term drug safety was excellent. After approximately ten months of treatment, skin sclerosis, as evaluated by a semiquantitative method, was markedly improved in 75{\%} of the cases. Stabilization of the clinical signs and symptoms was also observed and in two cases of generalized morphoea continued administration was regarded as unnecessary. On the other hand, the efficacy of factor XIII on organ involvement proved unclear even though its administration in combination with traditional drugs, such as low-dose corticosteroids or D-penicillamine, seemed to improve respiratory function in several cases As a consequence, factor XIII can be propsed both as the choice treatment in generalized morphea accompanied by ingravescent skin sclerosis, and as a drug to be combined with traditional treatments in systemic scleroderma.",
keywords = "Factor XIII, Generalized morphoea, Localized morphoea-systemic scleroderma",
author = "Marzano, {A. V.} and G. Gasparini and C. Colonna and E. Berti and R. Caputo",
year = "1995",
language = "English",
volume = "5",
pages = "459--466",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Treatment of systemic scleroderma and generalized morphoea with coagulation factor XIII

AU - Marzano, A. V.

AU - Gasparini, G.

AU - Colonna, C.

AU - Berti, E.

AU - Caputo, R.

PY - 1995

Y1 - 1995

N2 - In the blood coagulation process, factor XIII is responsible for the stabilization of the fibrin clot. Thivolet et a. [10] have used this factor in the treatment of scleroderma, hypothesizing as to its ability to favour the degradation of the collagen that accumulates in the skin and in other affected organs. Based on these findings and on the in vitro studies of Paye et al. [24], we administered factor XIII to twelve patients, eight of whom were suffering from sys temic scleroderma, three from generalized morphoea and one from localized morphoea. All had severe, widespread skin sclerosis. The mean duration of treatment was 35.5 months. Both short- and long-term drug safety was excellent. After approximately ten months of treatment, skin sclerosis, as evaluated by a semiquantitative method, was markedly improved in 75% of the cases. Stabilization of the clinical signs and symptoms was also observed and in two cases of generalized morphoea continued administration was regarded as unnecessary. On the other hand, the efficacy of factor XIII on organ involvement proved unclear even though its administration in combination with traditional drugs, such as low-dose corticosteroids or D-penicillamine, seemed to improve respiratory function in several cases As a consequence, factor XIII can be propsed both as the choice treatment in generalized morphea accompanied by ingravescent skin sclerosis, and as a drug to be combined with traditional treatments in systemic scleroderma.

AB - In the blood coagulation process, factor XIII is responsible for the stabilization of the fibrin clot. Thivolet et a. [10] have used this factor in the treatment of scleroderma, hypothesizing as to its ability to favour the degradation of the collagen that accumulates in the skin and in other affected organs. Based on these findings and on the in vitro studies of Paye et al. [24], we administered factor XIII to twelve patients, eight of whom were suffering from sys temic scleroderma, three from generalized morphoea and one from localized morphoea. All had severe, widespread skin sclerosis. The mean duration of treatment was 35.5 months. Both short- and long-term drug safety was excellent. After approximately ten months of treatment, skin sclerosis, as evaluated by a semiquantitative method, was markedly improved in 75% of the cases. Stabilization of the clinical signs and symptoms was also observed and in two cases of generalized morphoea continued administration was regarded as unnecessary. On the other hand, the efficacy of factor XIII on organ involvement proved unclear even though its administration in combination with traditional drugs, such as low-dose corticosteroids or D-penicillamine, seemed to improve respiratory function in several cases As a consequence, factor XIII can be propsed both as the choice treatment in generalized morphea accompanied by ingravescent skin sclerosis, and as a drug to be combined with traditional treatments in systemic scleroderma.

KW - Factor XIII

KW - Generalized morphoea

KW - Localized morphoea-systemic scleroderma

UR - http://www.scopus.com/inward/record.url?scp=0028828618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028828618&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028828618

VL - 5

SP - 459

EP - 466

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 6

ER -